CorMedix share price today

CorMedix Inc.'s share price was $5.66 at the close on 4 November 2026. It has been falling for 2 weeks. That is 26.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $13, and at that close it was at the low of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today CorMedix Inc. is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 11 weeks running.

Over the last 10 years the share price moved −37% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 21 August 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

CorMedix Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

CorMedix is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

CorMedix Inc. earned $25.8 M of net profit in the Jun 2026 quarter, +31.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $162 M. That is 25.3% of the quarter's revenue. The same quarter a year earlier earned $19.7 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

5 of the last 12 reported quarters were loss-making.

Why profit moved: revenue changed +156.5% on a year earlier and the margin moved −7.1 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +38.3% and revenue +376.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

CorMedix Inc. reported $102 M of revenue in the Jun 2026 quarter, +156.5% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 535.6% a year on average. The last full year, FY25, came in at $312 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $462 M.

FY25 revenue was $312 M, +617.0% on the year before.

Recent pace: the last four quarters grew +376.2% on average, against 535.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +280.5%, against +2,213.0% a year over the last 8 quarters (rolling over).

CorMedix Inc.'s operating margin was 42.1% in the Jun 2026 quarter, 7.1 percentage points lower than the same quarter a year ago. Across 4 years it has been between −47,113.8% and 51.4%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −7.1 percentage points on the year while gross margin changed −9.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

CorMedix Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $175 M of operating cash against $162 M of profit. After $2.3 M of spending on assets, $173 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

CorMedix Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.6 M on assets over the last 3 years. Averaged over those years that is 0.3% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $2.6 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

CorMedix Inc.'s P/E is 2.7×, about the lowest it has ever been. Its usual P/E (the middle reading) is 4.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

CorMedix Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

CorMedix Inc. earned a ROE of 40% in FY25. That is up from a low of −54% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −2,428%, a number that says nothing useful about the business. It comes from a 52.0% net margin and 0.38× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 52.0% net margin × 0.38× asset turnover × 2.04× leverage (assets divided by equity) ≈ 40.3% on equity. The margin does most of the work; borrowing is a big part of it.

CorMedix Inc. has total debt of $147 M against shareholder equity of $461 M as of Jun 2026, so its debt is 0.32× its equity. Year by year, that ratio went from 0.01 in FY21 to 0.37 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

22.3% of CorMedix Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 14.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For CorMedix Inc., the Z-score is 2.57. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 2.57 is in the grey area, neither clearly safe nor clearly in trouble.

There is no score against its industry: CorMedix Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

CorMedix is the 150th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: MiMedx Group, Inc., Phathom Pharmaceuticals, Inc. and Oculis Holding AG. Just below it: Prothena Corporation plc, Prelude Therapeutics Incorporated and Editas Medicine, Inc.

Biotechnology companies close in size

147. MiMedx Group, Inc. $467 million
148. Phathom Pharmaceuticals, Inc. $451 million
149. Oculis Holding AG $449 million
150. CorMedix Inc. $441 million
151. Prothena Corporation plc $431 million
152. Prelude Therapeutics Incorporated $420 million
153. Editas Medicine, Inc. $418 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2931. Value Line, Inc. $434 million · Financial Data & Stock Exchanges
2932. BrightSpire Capital, Inc. $434 million · REIT - Mortgage
2933. CorMedix Inc. $433 million
2934. Barnes & Noble Education, Inc. $433 million · Specialty Retail
2935. Gladstone Capital Corporation $433 million · Asset Management